|
||||||
Recent Issues2010Spring Summer 2009 April June August October/November Winter 2009–2010 2008 May/June July/August September/October November/December 2007 February April June August October December 2006 February April June August October December 2005 February April June August October December 2004 March May July/August September October December About Biotechnology Healthcare JournalRate CardProduction Specifications Call for Papers Conflict-of-interest form (PDF) Writers’ Guidelines Masthead Editorial Board Subscriptions Reprints |
May/June 2008FeaturesCover Story Translating Cancer Trial Endpoints into the Language of Managed CareThe terminology used in clinical trials means something to researchers and trial sponsors, but what does it mean for you? More importantly, how should you use it to evaluate a therapy or to make coverage decisions? Diagnostics Tumor Markers: A New Standard of Breast Cancer CareControversy about the reliability of genetic tests to predict treatment response raises the question: What should you look for to know whether a test has value? The answer may lie in the same principles that guide drug development. Cost Management They Provide the Proof When Tough Decisions Have To Be MadeIn a perfect world, payers would hire decision makers with a combination of attributes: a scientific understanding of biologics, the ability to get along with physicians, and managed care smarts. Meet SelectHealth’s biologics go-to team. Employers Flexibility in Biologic Benefit Designs Can Deliver Big RewardsPitney Bowes led the way. Now, more and more forward-thinking employers have bought into the idea: Make medications that help to keep workers productive available at little or no cost to the employee. Clinical MRSA: The Private-Sector ResponseThe market for effective infection-control interventions is growing. Products that merge information technology
with biotechnology can improve quality of care, reduce unnecessary suffering, and eliminate waste of resources. DepartmentsOpeners Winds of ChangeWelcome to our new look and focus, and to the era of the digital edition. Editorial The Savvy ShopperWe hear what you want, says David B. Nash, MD, MBA. Drug Track Research, Conferences, and FDA ActionsApprovals and other FDA actions, clinical research, and major conference coverage. Personalized Medicine What the Devil Is Personalized Medicine?It’s a term that means something different to almost everyone. So, what the devil is it? At a Glance Solid Tumors: Prevalence, Economics, and Implications for Payers and PurchasersPrevalence of disease, economics of care, and implications for payers, as told in charts. Biotechnology Healthcare’s 2007 Editorial IndexBiotechnology Healthcare’s 2007 index. Trends Out-of-Pocket Expenses Can Soar With 4th-Tier DrugsWhen good drugs go 4th tier. |
|||||